-The Economic Times KOLKATA: The holy Ganga is a poison river today. It's so full of killer pollutants that those living along its banks in Uttar Pradesh, Bihar and Bengal are more prone to cancer than anywhere else in the country, says a recent study.  Conducted by the National Cancer Registry Programme (NCRP) under the Indian Council of Medical Research, the national study throws up shocking findings. The river is thick with...

-The Times of India In a major move aimed at checking unnecessary medical tests and procedures, the health ministry on Sunday said it was working on a plan to make it mandatory for all private hospitals to declare and display the treatment costs of different diseases. Jagdish Prasad, director general of health services (DGHS), told TOI that the ministry's plan would check overbilling and bring in transparency in the healthcare sector. "Our aim...

-The Times of India  Strong control over morphine — a highly effective painkiller that has left millions of Indians in needless pain — has left India red-faced on the global stage. Calling use of opioid analgesics like morphine "sub-optimal" in India, the World Health Organization (WHO) on Wednesday asked India to immediately reassess regulatory requirements on the dispensing of essential medicines like morphine to ensure their wider availability and accessibility besides sensitizing...

-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...

-The Telegraph Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched. But the court described its scheme of classifying people on the basis of their incomes as “too complicated” and again urged the company to reduce prices. Whatever the scheme, the end result...